Literature DB >> 33785905

Aldosterone-producing adenoma associated with non-suppressed renin: a case series.

Pieter Martijn Jansen1, Michael Stowasser2.   

Abstract

Although the aldosterone/renin ratio (ARR) is the preferred screening test for primary aldosteronism (PA), patients with non-suppressed renin and a falsely negative ARR on non-interfering medications have occasionally been reported. This report describes the clinical characteristics and outcomes of seven patients with proven aldosterone-producing adenoma (APA) and non-suppressed renin.Chart review of seven PA patients with an APA and a non-suppressed plasma renin concentration (PRC > 8.4 mU/L) was undertaken to collect data on anthropometric and biochemical characteristics, diagnostic evaluation and postsurgical outcomes.Seven patients (two women and five men) with a proven APA had median (range) PRC, plasma aldosterone and ARR of 20 (9-43) mU/L, 750 (270-1940) pmol/L and 45 (8-62, normal <70), respectively, on non-interfering medications. Six patients had two consecutive ARR measurements and in five of them both were normal. Renal artery stenosis was carefully excluded in all patients. Further evaluation for PA was pursued because of high clinical suspicion (either hypokalaemia and/or a known adrenal mass lesion on imaging). All underwent adrenal vein sampling confirming unilateral PA which was managed by unilateral adrenalectomy. Postsurgical follow-up data either confirmed or were highly suggestive of cure of PA.Strict control of factors known to influence the ARR is crucial to avoid false-negative results. Other causes that could explain a non-suppressed renin should be excluded. In patients with a consistently non-suppressed renin further diagnostic workup for PA should be considered if clinical suspicion remains high.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33785905     DOI: 10.1038/s41371-021-00525-4

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  33 in total

1.  Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.

Authors:  V M Montori; G L Schwartz; A B Chapman; E Boerwinkle; S T Turner
Journal:  Mayo Clin Proc       Date:  2001-09       Impact factor: 7.616

2.  Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.

Authors:  Paolo Mulatero; Franco Rabbia; Alberto Milan; Cristina Paglieri; Fulvio Morello; Livio Chiandussi; Franco Veglio
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

3.  Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients.

Authors:  Ashraf H Ahmed; Michele Calvird; Richard D Gordon; Paul J Taylor; Gregory Ward; Eduardo Pimenta; Ross Young; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

4.  Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study.

Authors:  P M Jansen; F Boomsma; A H van den Meiracker
Journal:  Neth J Med       Date:  2008-05       Impact factor: 1.422

5.  Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism.

Authors:  Pieter M Jansen; Bert-Jan H van den Born; Wijnanda J Frenkel; Emile L E de Bruijne; Jaap Deinum; Michiel N Kerstens; Yvo M Smulders; Arend Jan Woittiez; Johanna A M Wijbenga; Robert Zietse; A H Jan Danser; Anton H van den Meiracker
Journal:  J Hypertens       Date:  2014-01       Impact factor: 4.844

6.  Contribution of the renin-angiotensin system and of the sympathetic nervous system to blood pressure homeostasis during chronic restriction of sodium intake.

Authors:  M Volpe; G Lembo; A Morganti; M Condorelli; B Trimarco
Journal:  Am J Hypertens       Date:  1988-10       Impact factor: 2.689

7.  The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling.

Authors:  Sau-Cheung Tiu; Cheung-Hei Choi; Chi-Chung Shek; Ying-Wai Ng; Fredriech K W Chan; Chiu-Ming Ng; Alice P S Kong
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

8.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 9.  The current epidemic of primary aldosteronism: causes and consequences.

Authors:  Norman M Kaplan
Journal:  J Hypertens       Date:  2004-05       Impact factor: 4.844

10.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

View more
  1 in total

Review 1.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.